Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

29.67 +0.79 (+2.74%)
Streaming Delayed Price Updated: 10:05 AM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 190,152
Open 28.75
Bid (Size) 29.60 (500)
Ask (Size) 29.68 (200)
Prev. Close 28.88
Today's Range 28.75 - 29.68
52wk Range 16.24 - 45.30
Shares Outstanding 308,456,852
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗
It has been a banner year for biotech buyouts, and these are two of the prime targets. 
Via The Motley Fool
News headline image
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement 
From Calidi Biotherapeutics, Inc
Via GlobeNewswire

Performance

YTD
+37.9%
+37.9%
1 Month
+16.3%
+16.3%
3 Month
+64.0%
+64.0%
6 Month
+37.8%
+37.8%
1 Year
-16.4%
-16.4%

More News

Read More
News headline image
Legend Biotech Corporation Announces Pricing of Public Offering
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech (NASDAQ:LEGN) Q1 2026 Revenue Surges on CARVYKTI Growth, but EPS Falls Short ↗
Via Chartmill
News headline image
Legend Biotech Corporation Announces Proposed Public Offering
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Legend Biotech USA Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
News headline image
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use ↗
Via MarketBeat
News headline image
Legend Biotech Announces Presentations at ASCO 2026
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
With YMM Down 29%, First Beijing Bought 13 Million More Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Legend Biotech (LEGN) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Legend Biotech Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Is Yum China a Buy After Investment Firm Matthews Purchased Shares Worth $12.57 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Matthews Just Slashed Its Futu Position -- Here’s Why That Matters ↗
Via The Motley Fool
News headline image
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Why Legend Biotech Stock Crushed the Market on Monday ↗
Via The Motley Fool
News headline image
Legend Biotech (LEGN) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Legend Biotech (LEGN) Q2 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Legend Biotech (LEGN) Q4 2024 Earnings Transcript ↗
Via The Motley Fool
Topics Earnings Economy World Trade

Frequently Asked Questions

Is Legend Biotech Corporation - American Depositary Shares publicly traded?
Yes, Legend Biotech Corporation - American Depositary Shares is publicly traded.
What exchange does Legend Biotech Corporation - American Depositary Shares trade on?
Legend Biotech Corporation - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Legend Biotech Corporation - American Depositary Shares?
The ticker symbol for Legend Biotech Corporation - American Depositary Shares is LEGN on the Nasdaq Stock Market
What is the current price of Legend Biotech Corporation - American Depositary Shares?
The current price of Legend Biotech Corporation - American Depositary Shares is 29.67
When was Legend Biotech Corporation - American Depositary Shares last traded?
The last trade of Legend Biotech Corporation - American Depositary Shares was at 07/01/26 10:05 AM ET
What is the market capitalization of Legend Biotech Corporation - American Depositary Shares?
The market capitalization of Legend Biotech Corporation - American Depositary Shares is 9.15B
How many shares of Legend Biotech Corporation - American Depositary Shares are outstanding?
Legend Biotech Corporation - American Depositary Shares has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.